Brian Colin Horsburgh
Vorstandsvorsitzender bei Modulate Therapeutics, Inc.
Profil
Brian Colin Horsburgh is the founder of Nurel Therapeutics, Inc. He is currently an Independent Director at Oil Spill Response Ltd.
and a Director at Modulate Therapeutics, Inc. He previously worked as a Director-Business Development at IP Group Plc, as well as a Director at Azellon Ltd.
and Amaethon Ltd.
Dr. Horsburgh obtained a doctorate degree from the University of Cambridge.
Aktive Positionen von Brian Colin Horsburgh
Unternehmen | Position | Beginn |
---|---|---|
Modulate Therapeutics, Inc.
Modulate Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Modulate Therapeutics, Inc. develops a medicine compound designed to re-engage the immune system in order to recognize and eradicate neoplastic disease. The company was founded by September 29, 2015 and is headquartered in Montréal, Canada. | Vorstandsvorsitzender | - |
Oil Spill Response Ltd.
Oil Spill Response Ltd. Environmental ServicesIndustrial Services Oil Spill Response Ltd. provides oil spill remediation services. The firm also provides business projects, training and consultancy services. The company was founded in 1981 is headquartered in London, the United Kingdom. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Brian Colin Horsburgh
Unternehmen | Position | Ende |
---|---|---|
Amaethon Ltd.
Amaethon Ltd. Miscellaneous Commercial ServicesCommercial Services Amaethon Ltd. commercializes plant and microbial science research. It audits, assesses, and protects Centre for Novel Agricultural Products' (CNAP) intellectual property and utilizes the Centre's research by developing relationships with industry and through the formation of spinouts. The firm is proactive in evaluating research progress in CNAP and identifying new intellectual property through regular IP surgeries with CNAP researchers. The company was founded in 2003 and is headquartered in York, the United Kingdom. | Direktor/Vorstandsmitglied | - |
IP GROUP PLC | Corporate Officer/Principal | - |
Nurel Therapeutics, Inc.
Nurel Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nurel Therapeutics, Inc. was a biotechnology company. The company develops products to treat and manage pain and peripheral nerve damage and also develops products to vascular diseases. The company's products use a proprietary drug delivery technology derived from an 'inert' herpes simplex virus that provides gene based medicine. The company was headquartered in Pittsburgh, PA. | Gründer | - |
Azellon Ltd.
Azellon Ltd. Miscellaneous Commercial ServicesCommercial Services Azellon Ltd. develops stem cell therapy for the repair of avascular meniscal tears. The firm's meniscal repair technology combines bone marrow stem cells with a special membrane that helps to deliver the cells into the injured site. The company was founded by Anthony Hollander and Troels Jordansen in 2007 and is headquartered in London, the United Kingdom. | Direktor/Vorstandsmitglied | - |
Ausbildung von Brian Colin Horsburgh
University of Cambridge | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
IP GROUP PLC | Commercial Services |
Private Unternehmen | 5 |
---|---|
Azellon Ltd.
Azellon Ltd. Miscellaneous Commercial ServicesCommercial Services Azellon Ltd. develops stem cell therapy for the repair of avascular meniscal tears. The firm's meniscal repair technology combines bone marrow stem cells with a special membrane that helps to deliver the cells into the injured site. The company was founded by Anthony Hollander and Troels Jordansen in 2007 and is headquartered in London, the United Kingdom. | Commercial Services |
Nurel Therapeutics, Inc.
Nurel Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nurel Therapeutics, Inc. was a biotechnology company. The company develops products to treat and manage pain and peripheral nerve damage and also develops products to vascular diseases. The company's products use a proprietary drug delivery technology derived from an 'inert' herpes simplex virus that provides gene based medicine. The company was headquartered in Pittsburgh, PA. | Health Technology |
Amaethon Ltd.
Amaethon Ltd. Miscellaneous Commercial ServicesCommercial Services Amaethon Ltd. commercializes plant and microbial science research. It audits, assesses, and protects Centre for Novel Agricultural Products' (CNAP) intellectual property and utilizes the Centre's research by developing relationships with industry and through the formation of spinouts. The firm is proactive in evaluating research progress in CNAP and identifying new intellectual property through regular IP surgeries with CNAP researchers. The company was founded in 2003 and is headquartered in York, the United Kingdom. | Commercial Services |
Modulate Therapeutics, Inc.
Modulate Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Modulate Therapeutics, Inc. develops a medicine compound designed to re-engage the immune system in order to recognize and eradicate neoplastic disease. The company was founded by September 29, 2015 and is headquartered in Montréal, Canada. | Health Technology |
Oil Spill Response Ltd.
Oil Spill Response Ltd. Environmental ServicesIndustrial Services Oil Spill Response Ltd. provides oil spill remediation services. The firm also provides business projects, training and consultancy services. The company was founded in 1981 is headquartered in London, the United Kingdom. | Industrial Services |